Boxcman,Major media exposure coming...
For several days in September, in Rhodes Greece, the elite of the oncology community—academia and industry—will gather at the 33rd congress of the International Society of Oncodevelopmental Biology and Medicine (ISOBM). This prestigious event brings together the best and brightest of the global oncology community and, through several presentations regarding its RECAF™ technology, BioCurex will delineate its science (BOCX.PK) to many potential research and licensing partners from around the world.
Three members of BioCurex’s impressive scientific advisory board, including CEO Ricardo Moro will present (release—with bio’s-- below) on topics dealing with the company’s proprietary RECAF™ marker technology. Other presenters from the Advisory Board will be the highly regarded Dr. Philip Gold—whose work ushered in the modern era of human cancer marker research and diagnostics with his development of the CEA and PSA markers—the most employed cancer markers worldwide.
As well, Dr. Jose Uriel, a distinguished scientist with an impressive research and prolific publishing history will present “ The Physiological Role of AFP and its Cell Receptors” (RECAF™).
The ISOBM is one of the longest standing and best-reputed forums for cancer markers in the world and it publishes the journal “Tumor Biology”.
All of these high-level presentations will undoubtedly further educate peers both in academia and industry with the exciting and ongoing developments regarding BioCurex’s research, testing, and future initiatives. With this amount of expertise in the same locale, there will likely be many opportunities to expand and expose the benefits of both RECAF™ and BioCurex’s applications to the attendees.
Interestingly, one of the main sponsors of the Congress is Abbott Diagnostics (NYSE: ABT)—a BioCurex licensee. Needless to say, the association between the two companies, we believe, should open significant doors for both; given the potential of RECAF ™ technology.
News 
Market Data 
Discover 
